United-Guardian (NASDAQ:UG), a diversified manufacturer of pharmaceutical, cosmetic, and healthcare products, today reported its financial results for the full year ended December 31, 2025.
The company’s performance reflected a bifurcated market environment, where steady gains in its medical and pharmaceutical divisions were overshadowed by a significant downturn in its international cosmetic ingredients business.
For the full year 2025, United-Guardian reported net sales of $10,545,468, a 13% decrease compared to the $12,084,332 recorded in 2024.
Net income for the year was $2,105,738, or $0.46 per share, down from $3,250,875, or $0.71 per share, in the previous fiscal year.
The decline in profitability was primarily a result of lower sales volumes in high-margin cosmetic lines and the impact of fixed manufacturing costs on a reduced revenue base.
The company's cosmetic ingredient segment faced a "perfect storm" of regional and structural challenges throughout 2025.
Management cited weaker consumer demand in China—a historically vital market for the company’s specialty ingredients—alongside the negative impact of tariffs and a buildup of excess inventory at the distributor level.
These factors led to a marked reduction in new orders as global beauty brands adjusted their production schedules to align with slower sell-through rates.
In contrast, the company’s pharmaceutical and medical lubricant segments provided a resilient hedge against the cosmetic slump.
Sales of Renacidin® Irrigation Solution and the company's line of medical lubricants saw year-over-year growth, driven by consistent clinical demand and expanded usage in healthcare facilities.